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The human immunodeficiency virus (HIV) encodes a gene product, Vpr, which causes infected cells to arrest or delay in the G2 phase of
the cell cycle. The arrest in G2 is characterized by low levels of Cyclin B1-p34Cdc2 activity and corresponding inhibitory phosphorylation of
p34Cdc2. We find that Vpr directly inhibits the in vitro activity of a phosphatase, Cdc25C, which normally activates Cyclin B1-p34Cdc2.
Vpr binds to Cdc25C both in vitro and in mammalian cells. Vpr is also able to inhibit Cdc25C phosphatase activity in vitro although it binds
to a site on Cdc25C that is distinct from the catalytic site of the enzyme. Expression of both a catalytically active mutant of Cdc25C that has
reduced binding to Vpr as well as a catalytically inactive mutant of Cdc25C that retains binding to Vpr is able to largely overcome Vpr-
mediated G2 arrest. Finally, depletion of Cdc25C from cells also renders them partially resistant to the effects of Vpr.
D 2003 Elsevier Inc. All rights reserved.Keywords: Human immunodeficiency virus; Vpr protein; Cdc25CIntroduction
Because of their limited genome size, retroviruses exploit
normal host cellular processes to their replicative advantage.
Thus, each of the human immunodeficiency virus (HIV)
accessory gene products (vif, vpr, vpu and nef) interacts
with cellular factors either to affect some aspect of viral
replication and assembly or to evade host immunity. In
particular, the product of the vpr gene has been proposed to
interfere with host cell cycle progression to increase viral
burst size (Goh et al., 1998).
The vpr gene of HIV-1 encodes a 96-amino acid protein
that is highly conserved among all the primate lentiviruses.
While it appears to be dispensable for viral replication in
vitro, selective pressure for the maintenance of HIV-1
quasispecies expressing Vpr in primate hosts belies the
importance of Vpr function in vivo (Goh et al., 1998; Lang0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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ocytoplasmic shuttling protein and is one of the determi-
nants in targeting the viral preintegration complex to the
nucleus of macrophages (Heinzinger et al., 1994; Sherman
et al., 2001; Vodicka et al., 1998). HIV-1 Vpr has been
shown to decrease HIV mutation rate during reverse
transcription by recruiting uracil DNA glycosylase
(UNG) (Mansky et al., 2000). Vpr also causes both
primary and transformed cells to accumulate in the G2
phase of the cell cycle (He et al., 1995; Jowett et al., 1995;
Re et al., 1995; Rogel et al., 1995), a phenotype that is
separable from its nuclear targeting property and its
interaction with UNG. Vpr-mediated G2 arrest correlates
with its ability to increase expression from the HIV
promoter (Goh et al., 1998). Because induction of G2
accumulation of infected cells by chemical agents also
increases promoter activity and viral production (Gozlan
et. al., 1998), the enhancement of viral replication by Vpr
in G2 is likely due to an indirect effect of Vpr on the cell
cycle (Gummuluru and Emerman, 1999). It has been
proposed that this increase in viral replication in G2, while
modest, would nevertheless confer a selective advantage
for HIV to maintain Vpr function when the infected cell
has a limited half-life in vivo (Goh et al., 1998; Gummu-
luru and Emerman, 1999; Holte and Emerman, 2000).
Therefore, elucidation of the mechanism of interaction of
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understanding of the biology of HIV infection.
The transit of cells from G2 into mitosis is normally
controlled by the activity of the mitotic cyclin-dependent
kinase, Cyclin B1-p34cdc2 kinase complex (Coleman and
Dunphy, 1994). The activity of this kinase complex is
regulated at multiple levels, one of which is phosphoryla-
tion. Phosphorylation of p34cdc2 on Thr-161 by cyclin-
activating kinase (CAK) is essential for p34Cdc2 activity
and is constitutive throughout the cell cycle. The entry of
cells into mitosis from G2 is blocked by the phosphorylation
of p34Cdc2 on Thr-14 and Tyr-15 by the kinases Wee1 and
Myt1 while dephosphorylation of these residues by the dual-
specificity protein phosphatase Cdc25C catalyses the onset
of mitosis (reviewed in Draetta and Eckstein, 1997). The
activity of Wee-1 and Cdc25C are in turn also regulated byFig. 1. Binding of Vpr to gst-Cdc25C correlates with G2 arrest. (A) Different allele
vitro translated and labelled with [35S]-Trans label in a rabbit reticulocyte lysate s
proteins were immunoprecipitated with a rabbit anti-Vpr antibody (right hand pane
to either gst or gst-Cdc25C and bound proteins analysed by SDS-PAGE (shown in
293T cells were transfected with HA-tagged Vpr. Expression of Vpr is shown in th
HA-tagged Vpr were immunoprecipitated with anti-Cdc25C, and immunoprecipita
anti-HA (shown in the second and third lanes). The top bands in lanes 2 and 3 of
the Vpr lane is specific to cells transfected with Vpr.Cyclin B1-p34Cdc2 at the level of phosphorylation, creating
a positive feedback loop to control entry into mitosis.
Cells expressing Vpr have very low or undetectable
Cyclin B1-p34Cdc2 kinase activity, consistent with an
arrest of cells in G2 by Vpr (He et al., 1995; Re et al.,
1995). However, the protein levels of Cyclin B1 and
p34Cdc2 in T cells that have been synchronized and
infected by wild-type HIV are similar to cells infected by
HIV not expressing Vpr, and Vpr does not inhibit Cyclin
B1-p34Cdc2 activity directly (unpublished observations).
Therefore, it is reasonable to infer that Vpr subverts cell
cycle progression by interacting with factors upstream of
Cyclin B1-p34Cdc2.
In this study, we show that Vpr is able to associate with
Cdc25C on a site that lies near, but distinct from the
catalytic domain of Cdc25C. Nonetheless, Vpr can directlys of Vpr corresponding to wild-type Vpr, mutants R90K and H71R were in
ystem. To determine the amount of Vpr used for binding, in vitro-translated
l). In vitro-translated lysates were incubated with glutathione beads coupled
left hand panel). (B) Vpr co-immunoprecipitates with endogenous Cdc25C.
e first lane. 293T cells that were either mock transfected or transfected with
tes were analysed for the presence of Vpr by Western blot and probing with
the IP-Western is non-specific detection of the IgG, while the lower band in
W.C. Goh et al. / Virology 318 (2004) 337–349 339inhibit the phosphatase activity of Cdc25C in vitro toward
both an artificial substrate and toward Cyclin B1-p34Cdc2.
Expression of a catalytically active mutant Cdc25C thatFig. 2. Mapping of Vpr binding domain on Cdc25C by deletion and site-directed m
translated Vpr. In vitro-translated Vpr was incubated with beads coupled to either g
C215 or gst-VPRBD and bound Vpr was analysed by SDS-PAGE. The grey shaded
least 20% recovery of bound radioactivity compared to the total input of in vitro-tr
as negative for binding. Single amino acid changes were also introduced into gst-C
are shown in red. (B) In vitro-translated HA-Vpr was incubated with gst, gst-C215
total amount of gst and gst fusion proteins used for binding in vitro-translated HA
was determined by immunoprecipitating in vitro-translated lysates with a monoclo
right panel). We often observe two forms of in vitro-translated HA-Vpr that bind
reactive with anti-HA antibody. It is presently unclear why we see two forms of HA
of HA-Vpr by contaminating proteases. (C) In vitro-translated HA-Vpr was incuba
gst and gst fusion proteins used are shown in the top panel. Bound proteins were an
of Cdc25 and the residues selected for site-directed mutagenesis.shows reduced inhibition by Vpr overcomes the block in
G2 more efficiently than wild-type Cdc25C. Furthermore,
expression of a catalytically inactive Cdc25C mutant thatutagenesis. (A) Deletion mutants of gst-C215 tested for binding to in vitro-
st, deletion mutants gst-C215d2, gst-C215d3, gst-C215d4, gst-C215d5, gst-
area denotes the minimal domain identified on gst-C215 that binds Vpr. At
anslated Vpr is scored as positive binding, while 2% or less recovery is read
215 by site-directed mutagenesis. The mutated E352K and K359E residues
or gst-C215 mutated at residue E352 or K359. Coomassie-stained gels of the
-Vpr are shown in the top panel. Total amount of HA-Vpr used for binding
nal anti-HA antibody. Bound proteins were analysed by SDS-PAGE (lower
to gst-C215 in our gst pull-down assays. Both forms appear to be variably
-Vpr but it is possible that the faster migrating protein is a cleavage product
ted with gst, gst-C215 or gst-C215 mutated at residue C377 or R383. Total
alysed by SDS-PAGE (lower right panel). (D) View of the catalytic domain
Fig. 2 (continued).
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arrest. Finally, depletion of Cdc25C by small-interfering
RNA reduces Vpr-induced G2 arrest, providing genetic
evidence that interaction of Vpr with the Cdc25C pathway
contributes to G2 arrest by Vpr in mammalian cells and is
likely important for its function during viral replication.Results
Association of Vpr with Cdc25C
It has been previously reported that Cdc25C is inactive
in cells that express Vpr (Re et al., 1995). We verified that
the active mitotic hyperphosphorylated forms of Cdc25C
are indeed absent in T cells that have been infected by HIVexpressing wild-type Vpr. The total amounts of Cdc25C
are not different in cells infected by wild-type HIV
compared to cells infected with HIV carrying a mutated
Vpr (data not shown). Thus, we asked if Vpr directly
affects Cdc25C by physical association. We find that in
vitro-translated wild-type Vpr binds Cdc25C expressed as
a gst fusion protein (Fig. 1A). The observed binding
appears to be functionally relevant because a Vpr mutant,
R90K, which is attenuated in G2 arrest, is attenuated in its
binding to gst-Cdc25C while a Vpr mutant, H71R, which
is deficient in G2 arrest, also binds gst-Cdc25C poorly
(Fig. 1A).
To determine if Vpr binds to endogenous Cdc25C in
mammalian cells, Vpr was fused to an epitope tag (HA-Vpr)
and transfected into 293T cells. Equal amounts of cellular
lysates were used for immunoprecipitating endogenous
Cdc25C with commercial anti-Cdc25C antibody coupled
to protein G-Sepharose beads. The immunoprecipitates were
then analysed by Western blotting for the presence of HA-
Vpr. Indeed, we were able to co-precipitate endogenous
Cdc25C with wild-type HA-Vpr (Fig. 1B). Thus, Vpr binds
to Cdc25C both in vitro and in vivo.
Identification of amino acids of Cdc25C that are important
for Vpr binding
Cdc25C encodes an amino-regulatory and carboxy-cata-
lytic domain. We found significant binding of HA-Vpr to
the carboxy terminus of Cdc25C (called gst-C215 here)
(Lee et al., 1992) (the C215 lane in Figs. 2A–C). Further
deletion analyses of gst-C215 showed that a minimal
domain between amino acids 334 and 379 of Cdc25C
upstream of the catalytic site was sufficient to bind Vpr
(Fig. 2A). To further identify residues within this domain of
Cdc25C that may be important for mediating this interaction
with Vpr, we took advantage of the published structures of
the catalytic domains of two homologues of Cdc25C—
Cdc25A and Cdc25B (Fauman et al., 1998; Reynolds et
al., 1999). Specific conserved amino acids were selected for
site-directed mutagenesis based on their predicted surface
accessibility for potential protein–protein interactions (Fig.
2D). Gst fusions of C215 mutated at two amino acids,
E352K and K359E, were tested for binding to in vitro-
translated Vpr. Coomassie-stained gels of gst and mutant
gst-C215 fusion proteins used in the binding assays show
that equal amounts of protein were used in the assay (Fig.
2B). Gst pull-down assays showed that mutation at residue
E352 (gst-C215 E352K) greatly reduced the binding of Vpr
to Cdc25C compared to wild-type gst-C215, while K395E
had a smaller effect (Fig. 2B, lower panel). Furthermore,
mutations at either residue C377 or R383 in the catalytic site
of gst-C215 abolish Cdc25C activity (Xu and Burke, 1996)
but still retain Vpr binding (Fig. 2C, lower panel). Thus, the
binding of Vpr to Cdc25C appears to involve predicted
surface residues that are distinct from the active site of the
enzyme.
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We next examined if the observed in vitro binding of
gst-Cdc25C to Vpr resulted in inhibition of Cdc25C
activity. Members of the Cdc25 phosphatase family hydro-
lyse the fluorescein derivative 3-O-methylfluorescein phos-
phate (OMFP) to OMF which can be followed by
absorbance at 477 nm (Eckstein et al., 1996; Gottlin et
al., 1996). To facilitate these experiments, purified gst
fusion to the carboxy catalytic domain of Cdc25C (gst-
C215) was used in subsequent analyses because expression
of the catalytic domain of Cdc25C was much higher in
Escherichia coli than full-length gst-Cdc25C. To test if
Vpr inhibits the activity of Cdc25C, we purified a histi-
dine-tagged recombinant Vpr (his-Vpr) from baculovirus-
infected insect cells (Fig. 3A). Indeed, we find that
recombinant his-Vpr inhibits the hydrolysis of OMFP by
gst-C215 (Fig. 3B). This suggests that Vpr directly inhibits
the phosphatase activity of the catalytic domain of Cdc25C
on an in vitro substrate. This inhibition of Cdc25C is
specific for wild-type Vpr as equivalent amounts of a his-
tagged Vpr mutant which does not cause G2 arrest (his-
H71R) do not inhibit the hydrolysis of OMFP by gst-C215
(Fig. 3B, recombinant protein shown in Fig. 3A). Con-
versely, a mutant of Cdc25C with reduced Vpr binding,
gst-C215 E352K (Fig. 2), exhibits less inhibition by Vpr
than gst-C215 in the OMFP assay (Fig. 3C). Thus, the
ability of Vpr to inhibit the activity of Cdc25C is corre-
lated with a functional Vpr and with a Cdc25C that is able
to bind Vpr. Taken together, these results indicate that Vpr
specifically associates with and inhibits the activity of
Cdc25C in vitro.
W.C. Goh et al. / VirFig. 3. Vpr inhibits gst-C215 hydrolysis of OMFP. (A) Gst-C215 hydrolysis of OM
tagged recombinant Vpr or recombinant H71R mutant using a Perkin-Elmer Lambd
Ag) or gst-C215 E352K (0.8 Ag) was carried out in the presence of equal amounts
the y-axis and time (s) is denoted on the x-axis.To examine if recombinant his-Vpr similarly inhibited
the activity of Cdc25C toward its physiological substrate,
Cyclin B1-p34Cdc2, we purified inactive forms of Cyclin
B1-p34Cdc2 kinase complex from irradiated Jurkat T cells
by immunoprecipitation with monoclonal antibodies
against Cyclin B1. Activation of Cyclin B1-p34Cdc2 by
recombinant gst-C215 was then measured by activated
Cyclin B1-p34Cdc2 kinase phosphorylation of H1 histone
in the presence of [g-32P]ATP. Addition of his-Vpr pre-
vented gst-C215 activation of Cyclin B1-p34Cdc2 (Fig.
4A) while similar amounts of his-H71R failed to inhibit
gst-C215 (Fig. 4B). To further test the specificity for both
Vpr binding and inhibition of Cdc25C, we compared the
activity of gst-C215 and gst-C215 E352K toward their
physiological substrate, Cyclin B1-p34Cdc2 in the pres-
ence of recombinant his-Vpr. Consistent with results
obtained with OMFP assays, Vpr inhibited activation of
Cyclin B1-p34Cdc2 by gst-C215, while an equal amount
of Vpr could not inhibit activation of Cyclin B1-p34Cdc2
by the mutant gst-C215 E352K (Fig. 4C). Thus, the
binding of Vpr to Cdc25C correlates with its in vitro
inhibition of Cdc25C activity toward both OMFP and
Cyclin B1-p34Cdc2.
Effect of wild-type and mutant Cdc25C overexpression on
Vpr-mediated G2 arrest in mammalian cells
The observed physical and functional association of
Cdc25C with Vpr predicts that overexpression of Cdc25C
should override G2 arrest by Vpr by providing excess
Cdc25C to compensate for the endogenous Cdc25C that is
inhibited by Vpr. Moreover, we would predict that aFP to OMF was monitored in the presence of equal amounts of histidine-
a 2S spectrophotometer. (B) Hydrolysis of OMFP to OMF by gst-C215 (0.8
of histidine-tagged Vpr. Optical density readings at 477 nm are denoted on
Fig. 4. Gst-C215 inhibition of Vpr toward Cyclin B1-p34Cdc2 kinase.
Activation of Cyclin B1-p34Cdc2 by gst-C215 (0.3 Ag) in the presence of
increasing amounts (0.1, 0.3, 1 Ag) of his-Vpr (panel A) or his-H71R (panel
B) was tested. Activation of Cyclin B1-p34Cdc2 was measured by its
ability to phosphorylate histone H1 in the presence of [g-32P]ATP. (C)
Activation of Cyclin B1-p34Cdc2 by gst-C215 was compared to its
activation by gst-C215 E352K in the presence of equal amounts of his-Vpr
(0.2 Ag of Vpr was used).
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Vpr (E352K) should override G2 arrest by Vpr to an even
greater extent than overexpression of wild-type Cdc25C
since none of the exogenously added Cdc25C mutant can
be inhibited by Vpr. To test these predictions, myc-tagged
fusions of a full-length E352K mutant of Cdc25C which
was only moderately inhibited by Vpr as a gst fusion protein
(Fig. 3B) or wild-type Cdc25C were transfected into HeLa
cells with a Vpr expression vector. While overexpression of
both forms of Cdc25C reduces G2 arrest by Vpr, we findthat expression of myc-Cdc25C E352K alleviated G2 arrest
by Vpr more efficiently than wild-type myc-Cdc25C in
HeLa cells (Figs. 5A–D). An example of the primary cell
cycle data for one experiment is shown in Fig. 5A. Note that
the G2/G1 ratio in the presence of Vpr is 0.8 and that it is
reduced to 0.66 in the presence of Cdc25C, and reduced
even more dramatically to 0.38 in the presence of the
Cdc25C mutant E352K. Fig. 5B shows similar results from
an experiment in which each transfection was done in
quadruplicate and the G2/G1 ratios were averaged. The
differential effect of Cdc25C versus Cdc25C E352K does
not appear to be due to a difference in expression levels of
myc-Cdc25C E352K and myc-Cdc25C (Fig. 5C) and is
consistent with the hypothesis that Vpr subverts cell cycle
progression through Cdc25C.
Similarly, we may expect that overexpression of a
catalytically inactive Cdc25C mutant that still binds Vpr
will alleviate G2 arrest by titrating Vpr away from endog-
enous Cdc25C. To test this hypothesis, we expressed an
inactive myc-tagged R383A mutant of Cdc25C that does
not bind its physiological substrate, Cyclin B1-p34Cdc2
(Xu and Burke, 1996) but retains binding to Vpr (Fig. 2C).
Indeed, we find that co-expression of Vpr and myc-Cdc25C
R383A reduced G2 accumulation of cells by Vpr (Fig. 5D,
values of quadruplicate transfections are shown). These
results are again consistent with the hypothesis that the
interaction between Vpr and Cdc25C contributes to G2
arrest.
Vpr-mediated G2 arrest of mammalian cells requires
Cdc25C
It was previously reported that cells lacking Cdc25C
generated from Cdc25C / mice have no deleterious
phenotype and have an intact G2 checkpoint (Chen et al.,
2001). However, inactivation of Cdc25C appears to result in
a delay in mitotic entry in HeLa cells (Bulavin et al., 2003).
Although Cdc25C is thought to be the major phosphatase
regulating the transition of cells from G2 into mitosis, the
delayed transit of cells into mitosis in the absence of
Cdc25C suggests that mammalian cells must have redun-
dant pathways to activate Cyclin B1-p34Cdc2 (Chen et al.,
2001). It has been suggested that other phosphatases such as
Cdc25B or Cdc25A may activate Cyclin B1-p34Cdc2 in the
absence of Cdc25C (Bulavin et al., 2001; Zhao et al., 2002).
Thus, we wished to test specifically whether Cdc25C is
required for the induction of cell cycle arrest by Vpr. To do
so, we depleted endogenous levels of Cdc25C using small
interfering RNAs (siRNA) (Elbashir et al., 2001). HeLa
cells were transfected twice at 24-h intervals with siRNA
homologous to nucleotides 198–218 in the amino terminus
of Cdc25C. Analysis by Western blotting showed that
Cdc25C protein levels were reduced to the limit of detection
(at least a 10-fold reduction) by our anti-Cdc25C antibody
over a 48-h time course after transfection with siRNA (Fig.
6A). Importantly, depletion of Cdc25C also reduced the
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control siRNA corresponding to luciferase did not affect G2
arrest by Vpr (Fig. 6B). It is presently unclear if the residual
G2 arrest phenotype observed after depletion of Cdc25C by
siRNA results from incomplete knockdown of Cdc25C
expression or if arrest of cells in G2 results from the
interaction of Vpr with several cellular components. These
results, however, indicate that Vpr-mediated G2 arrest
involves at least in part, the participation of Cdc25C.Discussion
G2 arrest of infected cells is a well-conserved property
among all HIV-1 and HIV-2/SIV vpr alleles (Planelles et al.,Fig. 5. Expression of myc-Cdc25C and myc-Cdc25C E352K alleviates G2 arrest b
transfected, co-transfected with EGFP and myc-Cdc25C, EGFP and myc-Cdc25C
myc-Cdc25C or CSVprCG and myc-Cdc25C E352K. Co-transfections of CSVprC
in quadruplicate. Flow diagrams are of GFP+ cells 48 h after transfection. The y-a
summarizing flow data from quadruplicate co-transfection experiments described
transfected with either myc-Cdc25C or myc-Cdc25C E352K. Cell lysates were pr
were either mock-transfected, transfected with myc-Cdc25C, myc-Cdc25C R3
CSVprCG and myc-Cdc25C R383A. Co-transfections were carried out in triplica
ratios were calculated after analysis by the Multicycle AV program.1996; Stivahtis et al., 1997). This phenotype is likely related
to a function that confers an advantage to the replication
cycle of HIV within the host because wild-type vpr alleles
are selected for in vivo (Lang et al., 1993; Goh et al., 1998).
G2 arrest by Vpr does not appear to depend on p53 or the
ataxia-telangiectasia ATM protein (Bartz et al., 1996).
However, it appears to involve at least in part, activation
of another regulator of DNA damage, ATR (Roshal et al.,
2003). Okadaic acid, an inhibitor of Ser/Thr phosphatases
like protein phosphatase 2A (PP2A) and protein phospha-
tase 1, also overcomes the effect of Vpr on the cell cycle (Re
et al., 1995). PP2A has been reported to be important in
regulating diverse cellular functions and is thought to be
involved in negatively regulating Cdc25C during the G2/M
transition. Here we show that Vpr associates with a celly Vpr. (A) Representative flow data from HeLa cells that were either mock
E352K, CSVprCG (that expresses Vpr and EGFP) alone, CSVprCG and
G and myc-Cdc25C or CSVprCG and myc-Cdc25C E352K were carried out
xis denotes cell count and the x-axis represents DNA content. (B) Bar graph
in panel A. (C) Western blot of HeLa cells that were mock-transfected or
obed with a mouse monoclonal anti-myc antibody (Babco). (D) HeLa cells
83A, CSVprCG or co-transfected with CSVprCG and myc-Cdc25C or
te. Cell cycle analyses are of GFP+ cells 48 h posttransfection. The G2/G1
Fig. 5 (continued).
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controls the transition of cells from G2 into mitosis. We
detect an association of Vpr with Cdc25C, both in vitro and
in vivo, which correlates with Vpr cell cycle arrest pheno-
type. Furthermore, binding of Vpr to Cdc25C inhibits the
activity of Cdc25C toward both an in vitro substrate, OMFP,
as well as its natural substrate, Cyclin B1-p34Cdc2. Con-
sistent with these findings, expression of an enzymatically
active Cdc25C mutant that is less inhibited by Vpr overrides
Vpr-mediated G2 arrest in mammalian cells more efficiently
than wild-type Cdc25C. Expression of an inactive Cdc25C
mutant that binds Vpr also reduces G2 accumulation by Vpr,
presumably by titrating Vpr molecules away from endoge-
nous Cdc25C. Thus, our results suggest that binding of
Cdc25C by Vpr may lead to G2 arrest.
Depletion of endogenous Cdc25C by siRNA also sig-
nificantly reduces Vpr-mediated accumulation of cells in
G2, suggesting that Cdc25C is involved in Vpr-mediated
G2 arrest. Although depletion of endogenous Cdc25C in
HeLa cells has been reported to result in a partial delay of
entry of cells into mitosis (Bulavin et al., 2003), Cdc25C
does not appear to be necessary for the G2 checkpoint
(Chen et al., 2001). Thus, our results point out a paradoxin that inhibition of Cdc25C by Vpr results in G2 arrest,
while the absence of Cdc25C does not result in G2 arrest.
To explain this paradox, we hypothesize that Cdc25C
bound to Vpr and Cyclin B1-p34Cdc2 has a dominant
interfering effect on the ability of other phosphatases to
activate Cyclin B1-p34Cdc2. In other words, binding of
Cdc25C and Vpr on Cyclin B-p34Cdc2 may block access
of other phosphatases to Cyclin B-p34Cdc2. However, it
remains possible that Vpr may also interact with other
cellular factors to prevent activation of Cyclin B-p34Cdc2
[Roshal et al., 2003].
The exact mechanism of inhibition of Cyclin B-p34cdc2
activity is currently unclear but does not appear to be the
result of a competitive inhibition of the catalytic activity of
Cdc25C by Vpr. While we describe a minimal binding
domain for Cdc25C, other nearby residues also contribute
to binding (data not shown). It is possible that the interac-
tion of Vpr with Cdc25C induces a conformational change
in Cdc25C that affects its activity. Because both Vpr and
Cdc25C actively shuttle between the cytoplasm and the
nucleus (Davezac et al., 2000; Jenkins et al., 2001; Sherman
et al., 2001; Yang et al., 1999), it is unclear where the site of
inhibition occurs. It is increasingly recognized that regula-
tion of the cell cycle is coordinated at multiple levels both
temporally and spatially (Pines, 1999a,b). In fact, the
activation of G2 arrest and then the maintenance of that
arrest may require both the blocking of the enzymatic
activity of the mitosis-promoting complex as well as the
active exclusion of the mitotic regulators from the nucleus
(Chan et al., 1999; Piwnica-Worms, 1999). Recently, it was
reported that expression of Vpr in mammalian cells results
in transient localized disruptions in the nuclear envelope that
correlate with G2 arrest (de Noronha et al., 2001), raising
the possibility that the release of cell cycle regulators into
the cytoplasm through these nuclear envelope disruptions
and the inhibition of their activity may both contribute to G2
arrest.
Vpr has been reported to have pleiotropic effects in
mammalian cells. Besides increasing viral replication and
inducing G2 arrest, it is thought to play a role in nuclear
transport of the viral preintegration complex (Heinzinger et
al., 1994) as well as in increasing apoptosis of infected cells
(Stewart et al., 1997). It has also been shown to result in
aberrant mitotic events and inhibit cell proliferation of
certain cell lines (Minemoto et al., 1999; Shimura et al.,
1999a,b). A few of these effects have been reported to be
conserved between mammalian cells and the fission yeast
Schizosaccharomyces pombe (Chen et al., 1999). Genetic
studies with the fission yeast S. pombe suggest that induc-
tion of the G2 phenotype in yeast involves several enzymes
that primarily include Wee1, the Ppa2 subunit of PP2A and
Rad 24 (Masuda et al., 2000; Zhao and Elder, 2000). More
recently, a role for Cdc25 has also been advocated in G2
arrest by Vpr in S. pombe (Elder et al., 2001). However,
how these different cell cycle regulators contribute to G2
arrest by Vpr remains to be elucidated.
Fig. 6. Depletion of endogenous Cdc25C alleviates Vpr-mediated G2 arrest. (A) HeLa cells were either mock-transfected (lane 1) or transfected with Cdc25C-
specific siRNA twice at 24-h intervals and analysed by Western blot for levels of Cdc25C at 24 h (lane 2), 48 h (lane 3) or 72 h (lane 4) after transfection. Cell
lysates were probed with a rabbit anti-Cdc25C antibody (Santa Cruz Technologies). (B) Cell cycle analyses of HeLa cells co-transfected with CSVprCG (that
expresses both Vpr and EGFP) and a non-relevant control siRNA (luciferase duplex siRNA) or Cdc25C siRNA. As controls for cells without Vpr, HeLa cells
were co-transfected with EGFP and luciferase or Cdc25C siRNA. Cell cycle analyses are of GFP+ cells. Cell number is denoted on the y-axis while DNA
content is on the x-axis. The G2/G1 ratios were calculated after analysis by the Multicycle AV program.
W.C. Goh et al. / Virology 318 (2004) 337–349 345Manipulation of the host cell cycle to its own advantage
is not unique to HIV and has been described for other DNA
and RNA viruses (Op De Beeck and Caillet-Fauquet,
1997)]. Although the best described cases are for viruses
that induce cells to enter S-phase, some viruses also cause
cell cycle arrest at the G2/M border. For example, reovirus
encodes a sigma-1s protein, the expression of which indu-
ces G2/M arrest and is associated with an inhibition of
Cdc25C activity, although there is no evidence that thisinhibition is direct (Poggioli et al., 2001). Baculovirus also
causes G2 arrest, although its mechanism appears to be
distinct from Cdc25C regulation (Belyavskyi et al., 1998;
Braunagel et al., 1998). Nonetheless, it is likely that there is
an evolutionary advantage for these viruses to alter their
host cell in a similar manner to HIV. We previously showed
that G2 arrest by Vpr increases viral burst size and
postulated that this may be a mechanism for selection of
this function in vivo (Holte and Emerman, 2000). Our
W.C. Goh et al. / Virology 318 (2004) 337–349346results suggest that the interaction of Vpr with Cdc25C may
contribute to the capacity of HIV to co-opt an important
cellular pathway for its own replicative advantage within
the host. However, a more complete understanding of the
interaction of Vpr with cell cycle progression will almost
certainly require detailed identification of the links between
the accumulation of active cyclins, the cyclin dependent
kinase complexes, and their regulators during normal tran-
sition of cells into mitosis.Materials and methods
Cells and reagents
Cell lines
Jurkat cells were maintained in RPMI with 10% fetal
bovine serum. HeLa cells were passaged in antibiotic-free
DME supplemented with 10% calf serum. 293Ts were
maintained in DME with 100 U of penicillin G and 100
Ag of streptomycin per ml and 10% fetal bovine serum.
Recombinant proteins
Wild-type Vpr and mutant H71R have previously been
described (Selig et al., 1997). These were overexpressed in
the pBlueBac-his system (Invitrogen). Recombinant his-
tagged proteins were purified from infected High Five cells
48 h after infection, lysed in 6 M deionised urea, 10 mM
Tris–HCl (pH 7.5), 100 mM NaH2PO4 and cell lysates
clarified by centrifugation. Cell lysates were passed over
nickel agarose beads according to the manufacturer’s rec-
ommendations. His-tagged proteins were refolded gently by
gradually decreasing the urea concentration and eluted with
buffer containing 20 mM PIPES pH 6.5, 150 mM KCl, 1.5
mM MgCl2, 0.5 mM DTT, 0.25 mM EDTA, 0.1% NP40
and 500 mM imidazole. Eluted proteins were dialysed
against 20 mM PIPES pH 6.5, 150 mM KCl, 1.5 mM
MgCl2, 0.5 mM DTT, 0.25 mM EDTA and 0.1% NP40 to
remove imidazole.
Recombinant gst-Cdc25 proteins were purified as de-
scribed (Ogg et al., 1994) except that bacterial cell pellets
were resuspended in STE (100 mM NaCl, 10 mM Tris–HCl
pH 8.0, 1 mM EDTA) supplemented with 2 mM PMSF, 20
AM pepstatin, 20 AM leupeptin, 0.15 U/ml aprotinin and 0.5
mg/ml lysozyme after IPTG induction. Triton X-100 was
added to a final concentration of 2% and bacterial lysates
were sonicated to complete lysis. Lysates were then clarified
by centrifugation and proteins were purified on glutathione
agarose beads, washed with STE containing 2% Triton X-
100 followed by STE. Proteins were eluted in 20 mM Tris–
HCl pH 8.0, 2 mM EDTA, 2 mM DTT, 150 mM NaCl and 5
mM glutathione. Recombinant gst-Cdc25 proteins used for
gst pull-down assays were dialysed against 20 mM Tris–HCl
pH 8.0, 2 mM EDTA, 2 mM DTT and 150 mM NaCl to
remove glutathione, quantitated by Bio-Rad protein assay
and re-bound to gst beads. The quantity of proteins bound togst beads was confirmed by SDS-PAGE and Coomassie
staining.
Site-directed mutagenesis
Mutations H340D, E352K, K359E, C377S and R383A
were introduced into gst-C215 using the QuikChange kit
(Stratagene) according to the manufacturer’s directions.
Mutations E352K, C377S and R383A were also introduced
into myc-Cdc25C in a similar manner.
Plasmids
The vpr gene was expressed from a vector containing
the simian CMV IE94 enhancer/promoter. This plasmid
was further modified to also encode the enhanced green
fluorescent protein (EGFP) expressed from a CMV pro-
moter (CSVprCG). A plasmid that only expresses EGFP
from a CMV promoter was used as control. The vector
containing only the simian CMV IE94 enhancer/promoter
(pCS2+) was also used as control filler plasmid in co-
transfection experiments.
Small interfering RNA
Twenty-one nucleotide RNA duplexes with 2 nucleotide
3V (2V-deoxy)-thymidine overhangs corresponding to
Cdc25C coding sequence were synthesized by Dharmacon
Research Incorp. RNA sequence of sense strand of Cdc25C
siRNA: 5V AACCCCAAAATGTTGCCTCGA(dTdT) 3V. A
control heterologous RNA duplex corresponding to lucifer-
ase coding sequence was purchased from Dharmacon Re-
search Incorp. RNA sequence of sense strand of luciferase
siRNA: 5V CGUACGCGGAAUACUUCGA(dTdT) 3V. The
sequences were confirmed by BLAST search to ensure that
they did not have significant sequence homology to any
other gene.
Flow cytometry
Cells were processed for cell cycle analysis 48 h after
transfection. After washing in PBS, infected cells were fixed
in 1% paraformaldehyde for at least an hour, then permea-
bilised for 5 min at room temperature with PBS containing
0.5% Tween. Cells were treated with RNase A (180 U/ml)
and either DAPI at 1 Ag/ml or propidium iodide at 50 Ag/ml
for 1 h to overnight before flow cytometric analysis. The
DNA profiles were analysed by the Multicycle AV Program
(Phoenix Flow Systems, San Diego, CA).
In vitro binding
Wild-type Vpr, Vpr mutants R90K, and H71R were
cloned into pGem11Zf vectors (Promega) as a hemagluti-
nin (HA)-fusion protein and in vitro translated using a
TNT-coupled reticulocyte lysate system (Promega) in the
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manufacturer’s recommendations. In vitro-translated
lysates were immunoprecipitated with either a rabbit anti-
Vpr or mouse anti-HA antibody and immunoprecipitated
proteins were quantitated using a PhosphorImager. Equal
amounts of in vitro-translated Vpr alleles were incubated
with gst fusion proteins coupled on glutathione beads in a
buffer containing 20 mM PIPES pH 6.5, 150 mM KCl, 1.5
mM MgCl2, 0.25 mM EDTA, 0.5 mM DTT, 0.1% NP40.
Binding was carried out in a final volume of 30 Al at 4jC
for at least 4 h. Bound proteins were washed at least five
times with binding buffer and then analysed by SDS-
PAGE. Binding is further quantified by analysis on a
PhosphorImager.
Co-immunoprecipitation assays
293T cells were transfected with hemaglutinin (HA)-
tagged wild-type Vpr, and lysed after 48 h in 50 mM
Tris–HCl pH 8.0, 5 mM EDTA, 100 mM NaCl, 0.5%
CHAPS, 1 Ag/ml leupeptin, 1 Ag/ml aprotinin and 2 mM
PMSF. To ensure that transfection efficiency was similar for
each plasmid, cell lysates were tested for expression of
transfected Vpr alleles by Western blot using a mouse anti-
HA antibody (Babco). Equal amounts of lysates were used
for immunoprecipitation with a rabbit anti-Cdc25C antibody
(Santa Cruz) conjugated to protein G-Sepharose beads.
Immunoprecipitates were washed at least five times with
lysis buffer and analysed by Western blot with mouse anti-
HA to test for the co-precipitation of HA-tagged Vpr with
Cdc25C.
OMFP assays
Reactions were carried out in 1 ml of 50 mM Tris–HCl
pH 8.2, 50 mM NaCl, 1 mM DTT, 200 AM OMFP and 20%
glycerol in a Perkin-Elmer Lambda 2S spectrophotometer,
set at a wavelength of 477 nm. Data were collected
continuously over the course of 10–30 min. Reactions with
recombinant his-tagged Vpr and mutant Vpr H71R were
carried out after incubation with gst-C215 or gst-C215
E352K on ice for an hour in a 10-Al reaction before adding
OMFP. Control reactions with gst-C215 or gst-C215 E352K
without Vpr were similarly performed after addition of an
equivalent volume of buffer that his-tagged Vpr was dia-
lysed against.
H1 histone kinase assays
To isolate inactive Cyclin B1-p34Cdc2, Jurkat cells
were irradiated at 600 rads in a Cesium source for 18 h,
lysed in 50 mM Tris–HCl pH 7.5, 120 mM NaCl, 0.5%
NP40, 50 mM sodium fluoride, 0.1 mM sodium orthova-
nadate, 1 Ag/ml aprotinin, 1 Ag/ml leupeptin and 2 mM
PMSF and immunoprecipitated with rabbit anti-Cyclin B1
antibody (Oncogene Sciences). Immunoprecipitates werewashed once with lysis buffer, twice with 50 mM Tris–
HCl pH 7.5, 250 mM NaCl and twice with 50 mM Tris–
HCl pH 7.5, 250 mM NaCl, 10 mM MnCl2, 1 mM DTT.
H1 histone kinase reactions were carried out by incubating
Cyclin B1-p34Cdc2 immunoprecipitates in 50 mM Tris–
HCl pH 7.5, 10 mM MnCl2, 1 mM DTT, 70 mM NaCl, 10
AM ATP, 80 mM h-glycerol phosphate, 50 mM NaF, 2 Ag
histone H1 and 0.01 mCi of [g-32P]ATP at 37jC for 30–
45 min.
For Cdc25 activation assays, Cyclin B1 complexes
were immunoprecipitated as described above. Immunopre-
cipitates were washed once with lysis buffer and then
three times with Cdc25 assay buffer (100 mM Tris–HCl
pH 7.5, 250 mM NaCl, 5 mM EDTA, 1 mM DTT).
Cyclin B1-p34Cdc2 complexes were then incubated with
gst-C215 or gst-C215 E352K fusion proteins with or
without recombinant Vpr in Cdc25 assay buffer for 30–
45 min at 37jC. In samples where recombinant Vpr was
not added, an equivalent volume of buffer that Vpr was
dialysed against was incubated with gst-C215 or gst-C215
E352K. Samples were then used for H1 kinase activity as
described above.
Co-transfection assay
HeLa cells (3  105) were plated in a 12-well plate in
antibiotic-free DMEM and 10% calf serum. Cells were co-
transfected with 0.8 Ag CSVprCG and 2 Ag of myc-
Cdc25C or myc-Cdc25C E352K or myc-Cdc25C R383A
using lipofectomine (Invitrogen) according to manufactur-
er’s recommendations. As control, 0.8 Ag CSVprCG was
co-transfected with 2 Ag of pBluescript or pCS2+. They
were analysed by flow cytometry 48 h after transfection.
Transfection of siRNA
HeLa cells (1  105) were plated in a 24-well plate in
antibiotic-free DMEM and 10% calf serum. Cells were
transfected with 60 pmol of siRNA duplex with Oligofect-
amine (Invitrogen-Gibco) twice at 24-h intervals according
to the manufacturer’s instructions. During the second
siRNA transfection, 0.1 Ag of a plasmid that expresses both
Vpr and a green fluorescent protein (called CSVprCG) was
included in the transfection mix. Cells were harvested for
cell cycle analysis 48 h after transfection. Cells were also
collected 24, 48 and 72 h after the second siRNA transfec-
tion and assessed for the amount of depletion of endogenous
Cdc25C by Western blot.Acknowledgments
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